Autolus Therapeutics Stock Forecast, Price & News

Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

Is Autolus Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Autolus Therapeutics stock.
View analyst ratings for Autolus Therapeutics or view top-rated stocks.

How has Autolus Therapeutics' stock been impacted by Coronavirus?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AUTL shares have decreased by 5.0% and is now trading at $6.43.
View which stocks have been most impacted by COVID-19.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,500,000 shares, an increase of 39.7% from the October 31st total of 1,790,000 shares. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 2.3 days.
View Autolus Therapeutics' Short Interest.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Autolus Therapeutics.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.04. Autolus Therapeutics had a negative net margin of 5,610.45% and a negative trailing twelve-month return on equity of 55.22%. During the same period in the previous year, the firm earned ($0.72) EPS.
View Autolus Therapeutics' earnings history.

What price target have analysts set for AUTL?

6 brokers have issued 12-month price targets for Autolus Therapeutics' shares. Their forecasts range from $9.00 to $21.00. On average, they expect Autolus Therapeutics' share price to reach $14.67 in the next twelve months. This suggests a possible upside of 128.1% from the stock's current price.
View analysts' price targets for Autolus Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:

• Christian Martin Itin, Chief Executive Officer & Director
• Christopher Vann, Chief Operating Officer & Senior Vice President
• Andrew J. Oakley, Chief Financial Officer & Senior Vice President
• Martin Pulé, Chief Scientific Officer & Senior Vice President
• David Brochu, Chief Technical Officer & Senior Vice President

Who are some of Autolus Therapeutics' key competitors?

Some companies that are related to Autolus Therapeutics include Sorrento Therapeutics (SRNE), C4 Therapeutics (CCCC), Krystal Biotech (KRYS), Vericel (VCEL), Alector (ALEC), Atara Biotherapeutics (ATRA), Immunocore (IMCR), Inhibrx (INBX), Coherus BioSciences (CHRS), REGENXBIO (RGNX), Replimune Group (REPL), Ocugen (OCGN), iTeos Therapeutics (ITOS), Sangamo Therapeutics (SGMO) and AlloVir (ALVR).
View all of AUTL's competitors.

What other stocks do shareholders of Autolus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD).

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pendal Group Ltd (1.94%), Millennium Management LLC (0.61%), Eversept Partners LP (0.55%), Morgan Stanley (0.27%), Granahan Investment Management Inc. MA (0.24%) and MYDA Advisors LLC (0.24%).

Which institutional investors are selling Autolus Therapeutics stock?

AUTL stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Millennium Management LLC, Granahan Investment Management Inc. MA, Morgan Stanley, Eversept Partners LP, UBS Group AG, and Lindbrook Capital LLC.

Which institutional investors are buying Autolus Therapeutics stock?

AUTL stock was purchased by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Cetera Investment Advisers, BlackRock Inc., MYDA Advisors LLC, Citadel Advisors LLC, GSA Capital Partners LLP, Jump Financial LLC, and Brighton Jones LLC.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $6.43.

How much money does Autolus Therapeutics make?

Autolus Therapeutics has a market capitalization of $468.87 million and generates $1.72 million in revenue each year. The company earns $-142.09 million in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

Autolus Therapeutics employs 2,020 workers across the globe.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is www.autolus.com.

Where are Autolus Therapeutics' headquarters?

Autolus Therapeutics is headquartered at FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 442038296230 or via email at [email protected].